MCIM
TVRD

Meadow Creek Investment Management’s Tvardi Therapeutics TVRD Stock Holding History

Meadow Creek Investment Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-60
Closed -$27K – 1340
2018
Q1 		$27K Sell
60
-180
-75% -$87.3K ﹤0.01% 1301
2017
Q4 		$106K Sell
240
-142
-37% -$64.7K ﹤0.01% 1187
2017
Q3 		$188K Sell
382
-48
-11% -$24K ﹤0.01% 936
2017
Q2 		$238K Sell
430
-143
-25% -$90.7K 0.01% 818
2017
Q1 		$379K Hold
573
– – 0.01% 615
2016
Q4 		$192K Buy
+573
New +$184K 0.01% 727

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Meadow Creek Investment Management's TVRD Position: Q2 2018 in Review

Meadow Creek Investment Management sold out of Tvardi Therapeutics (TVRD) in Q2 2018, closing a stake of 60 shares — an estimated $27K sold.

Meadow Creek Investment Management first reported a position in TVRD in Q4 2016 and held it in 6 quarters. The position peaked at $379K in Q1 2017. 130 funds tracked by Wall St. Rank hold TVRD as of Q2 2018.

  • Meadow Creek Investment Management reported no remaining Tvardi Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Meadow Creek Investment Management sold 60 Tvardi Therapeutics shares in Q2 2018, an estimated $27K.
  • Meadow Creek Investment Management first reported a position in Tvardi Therapeutics in Q4 2016 and held it in 6 quarters.
  • Meadow Creek Investment Management's Tvardi Therapeutics position peaked at $379K in Q1 2017.
  • 130 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2018.

Based on Meadow Creek Investment Management's 13F filing for Q2 2018, filed 10 Aug 2018.